Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the promise of faster, less toxic treatment without lymphodepletion while raising ...

Treatment for stage 3 myeloma is typically divided into phases. The goal is to achieve a deep remission, meaning the cancer ...

Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

The map was developed by using single-cell RNA sequencing to analyze 1.4 million plasma and immune cells in bone marrow from over 300 patients.

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...

Key abstracts on multiple myeloma from the 2025 American Society of Hematology Annual Meeting are reported by Dr Joseph Mikhael, chief medical officer of the International Myeloma Foundation. Dr ...

In June 2025, we reported on a study that showed long-term survival with undetectable disease in heavily pretreated multiple myeloma. The results not only added fresh evidence of efficacy for CAR ...

A new legislative push to make ivermectin available without a prescription in Wyoming is drawing sharp criticism from medical professionals, who warn the move could not only endanger ...

Ivermectin's reputation keeps growing as a kind of cure-all, even for cancer — despite evidence it doesn't work. Ivermectin is back. Ivermectin is a drug - a drug that gained notoriety as a disproven ...